Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)

Completed

• Conditions: Critical Illness; Kidney Injury; Pharmacokinetics
• Interventions: Other: serial serum sampling for quantification of drug concentration

• Registration Number: NCT02242006
• Lead Sponsor: Ottawa Hospital Research Institute

Brief Summary

Severe acute kidney injury (AKI) is a common complication of critical illness affecting almost half of all patients with septic shock. Extracorporeal renal replacement therapy is a cornerstone in the management of AKI in these patients. Options for renal replacement therapy include continuous renal replacement (CRRT) therapy, intermittent dialysis (IHD) or a hybrid form of the two called sustained low efficiency dialysis (SLED). Globally there is a push to switch from traditional CRRT to SLED. Although there are resource and financial comparative benefits to SLED there is almost no literature describing how to dose antimicrobials (or other drugs for that matter). It appears that drug clearance on SLED may be more efficient than CRRT but not as efficient as IHD making extrapolation from these bodies of literature inappropriate for SLED. The investigators are proposing to conduct the population pharmacokinetic studies for the three most commonly used antimicrobials in critically ill patients receiving SLED therapy (piperacillin-tazobactam, meropenem and vancomycin). Population pharmacokinetic modeling of these drugs will provide estimates and sources of variability around pharmacokinetic parameters that will subsequently be used for Monte Carlo simulation to determine the most appropriate dosing regimens to achieve therapeutic targets while minimizing the risk of toxicity.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2014-09
• Study First Submitted: 2014-09-09
• Study First Submitted QC: 2014-09-15
• Study First Posted: 2014-09-16
• Study Start: 2014-10
• Primary Completion: 2016-03
• Study Completion: 2016-03
• Last Update Submitted: 2021-04-27
• Last Update Posted: 2021-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Critically ill adults [age ≥ 18] admitted to one of two of the medical/surgical intensive care units (ICUs) of The Ottawa Hospital, who require SLED and are or will receive meropenem, piperacillin-tazobactam or vancomycin therapy at any dose.

Read More

Exclusion Criteria

• Patients for whom participation via the informed consent process is denied.
• Critically ill patients with a hypermetabolic state due to >25% coverage of body surface area burn, cystic fibrosis, spinal cord injury, bariatric patients (defined as >150kg total body weight)
• Patient is pregnant as per a positive serum or urine βHCG qualitative assay
• Patient does not have a closed-system arterial or central venous catheter (to minimize blood wastage)
• Patients receiving concomitant drugs known to interact with the metabolism or clearance of the antimicrobial of interest according to Micromedex 2.0 (Truven Health Analytics Inc 2013)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
vancomycin	serial serum sampling for quantification of drug concentration	Serial serum sampling of patients receiving vancomycin and SLED simultaneously
piperacillin/tazobactam	serial serum sampling for quantification of drug concentration	Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
meropenem	serial serum sampling for quantification of drug concentration	Serial serum sampling of patients receiving meropenem and SLED simultaneously

Primary Outcome Measures

Name	Time	Method
drug clearance	During the first run of SLED after study inclusion	Serial serum samples will be obtained after drug administration and during SLED to determine drug clearance during SLED.
volume of distribution	During the first run of SLED after study inclusion	Serial serum samples will be obtained after drug administration and during SLED to determine drug volume of distribition during SLED.

Trial Locations

Locations (1)

The Ottawa Hospital; 🇨🇦 Ottawa, Ontario, Canada